The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial

David P Dearnaley,Daniel R Saltzstein,John E Sylvester,Lawrence Karsh,Bryan A Mehlhaff,Christopher Pieczonka,James L Bailen,Hongliang Shi,Zhan Ye,Hélène M Faessel,Huamao Lin,Yanyan Zhu,Fred Saad,David B MacLean,Neal D Shore

European Urology（2020）

引用 42|浏览64

暂无评分

摘要

The phase 2 study C27003 demonstrated relugolix, an oral gonadotropin-releasing hormone antagonist, achieves and maintains testosterone castration for 24wk in >90% of men with localised intermediate- and high-risk prostate cancer requiring neoadjuvant and/or adjuvant androgen deprivation therapy to external beam radiation therapy.

查看译文

关键词

Prostate cancer,Androgen deprivation therapy,Relugolix,Degarelix,External beam radiotherapy,Gonadotropin-releasing hormone analogues,Neoadjuvant/adjuvant,TAK-385

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要